Factor XIII deficiency is a rare genetic blood disorder that is characterized by the deficiency of clotting factor XIII. Clotting factors are proteins that play an important role in blood clotting. Patients suffering from factor XIII deficiency are able to form clots, however, these clots are highly unstable and dissolve easily, which results in prolonged uncontrolled bleeding.
The severity and symptoms of the factor XIII deficiency vary from person to person thus the factor XIII deficiency treatment differs with respect to the severity. In most patients with factor XIII deficiency (80%), bleeding symptoms appear after birth, which includes bleeding from the umbilical stump. Other patients are likely to have only a mild expression of the factor XIII deficiency that can become more apparent in the later stages of life when they encounter a traumatic injury or surgery.
Factor XIII deficiency is a genetic disorder that is recessive in nature. Thus, the risk of two carrier parents passing both the altered genes to their offspring is about 25% with each pregnancy. In case the parents are close relatives of each other, the risk is much higher. Thus, in communities where consanguineous marriages are more common, the risk of factor XIII deficiency is higher in the offspring, hence, it is widely seen in such communities.
Get a sample of this report: https://www.factmr.com/connectus/sample?flag=S&rep_id=1348
Factor XIII Deficiency Treatment Market: Key Players
The global market for factor XIII deficiency treatment has two main pharmaceutical players, however, there are a number of blood banks that offer fresh frozen plasma. Companies that offer factor xiii concentrate are CSL Behring and Novo Nordisk, Inc. Examples of some of the blood banks that offer fresh frozen plasma for factor XIII deficiency treatment are Global Blood Fund, World Blood Bank, and other local blood banks.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The report covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint.
Factor XIII Deficiency Treatment Market: Segmentation
The global factor XIII deficiency treatment market can be segmented on the basis of treatment distribution channel and geography.
Based on treatment type, the global factor XIII deficiency treatment market is segmented as:
- Fresh frozen plasma treatment
- Pharmaceutical product treatment
Based on distribution channel, the global factor XIII deficiency treatment market is segmented as:
- Hospital pharmacies
- Retail pharmacies
- Blood banks